文献速递细胞病理与分子病理胸部病理

BAP1缺失与CDKN2A/p16纯合缺失检测提升积液细胞学中间皮增生的诊断准确性

Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
PubMed 文献 · Cancer Cytopathol · 2020-07-17

该回顾性研究纳入74例手术确诊恶性间皮瘤患者的99份配对积液细胞学标本,回顾性行BAP1免疫组化和p16 FISH检测。结果显示BAP1和/或p16缺失可将形态学诊断敏感性从30.3%提高至68.7%(P<.0001),并改变62%可解释积液标本的诊断解释(P=.07),胸水标本尤为显著(P=.002)。

要点

  • BAP1免疫组化联合p16 FISH可显著提高积液细胞学诊断间皮瘤的敏感性。
  • 联合检测可使部分病例在活检前9个月即提示恶性,实现更早诊断。
  • 胸水标本中联合检测对诊断解释的改变尤为显著(P=.002)。

核心结论

  • 常规使用BAP1免疫组化和p16 FISH作为辅助检测可提高细胞学标本诊断准确性,并可能实现恶性间皮瘤的更早诊断。

研究设计与样本

  • 回顾性研究,纳入74例手术确诊恶性间皮瘤患者的99份配对积液细胞学标本,其中上皮样67例、双相型7例、胸水55例、腹水19例。
  • 对标本回顾性行BAP1免疫组化和p16荧光原位杂交(FISH)检测。

主要发现

  • 原判为良性/反应性的18份样本中7份(39%)检出BAP1或p16缺失。
  • 可解释的非典型33份样本中20份(61%)检出缺失,可疑间皮瘤14份中10份(71%)检出缺失。
  • 判为恶性的30份样本中28份(93%)检出BAP1或p16缺失。
  • 部分病例可在活检前长达9个月即提示间皮瘤诊断,恶性类别中部分病例可提前6个月诊断。
  • BAP1和/或CDKN2A/p16纯合缺失会改变60份可解释积液标本中37份(62%)的诊断解释(P=.07),胸水中为48份中32份(P=.002)。

关键数值与推荐

  • 单独形态学判读的敏感性为30.3%,加做BAP1和p16检测后敏感性提高至68.7%(P<.0001)。

临床怎么用

  • 在积液细胞学评估间皮增生时,可常规加做BAP1免疫组化和p16 FISH作为辅助检测。
  • 联合检测结果有助于在组织活检前更早提示恶性间皮瘤,尤其适用于胸水标本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A number of ancillary tests have been developed that aid in the diagnosis of mesothelioma in cytology specimens. The aim of this retrospective study was to determine whether testing for BAP1 and CDKN2A/p16 status in effusion specimens preceding the tissue diagnosis of mesothelioma would improve diagnostic accuracy and allow an earlier diagnosis of malignancy. METHODS: The study cohort included 99 matched cytology fluid specimens from 74 patients with a surgical specimen diagnosis of malignant mesothelioma (67 epithelioid, 7 biphasic, 55 pleural, and 19 peritoneal). BAP1 immunohistochemistry and p16 fluorescence in situ hybridization (FISH) were performed retrospectively. RESULTS: BAP1 or p16 FISH testing revealed a loss in 7 of 18 (39%) samples originally categorized as benign/reactive, 20 of 33 (61%) interpretable samples categorized as atypical, and 10 of 14 (71%) cases suspicious for mesothelioma. In some cases, the diagnosis of mesothelioma could have been made up to 9 months before biopsy. Similarly, loss of BAP1 or p16 was found in 28 of 30 (93%) samples categorized as malignant, with some cases diagnosable up to 6 months before biopsy. Overall, loss of BAP1 and/or CDKN2A/p16 homozygous deletion would change the diagnostic interpretation in 37 of 60 (62%) (P = .07) effusion specimens, particularly in pleural effusions (32 of 48 samples) (P = .002). The sensitivity of morphologic interpretation alone was 30.3%; however, adding testing for BAP1 and p16 resulted in an increase in sensitivity to 68.7%. (P < .0001). CONCLUSION: These findings suggest that routine use of BAP1 immunochemistry and p16 FISH as adjunctive tests improves the diagnostic accuracy of cytology specimens and potentially allows an earlier diagnosis of malignant mesothelioma.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Chevrier M, Monaco SE, Jerome JA, et al. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology. Cancer Cytopathol. 2020. PMID: 32678499. doi:10.1002/cncy.22326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。